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To highlight methodologic challenges pertinent to design, analysis, and reporting of results of ran-
domized clinical trials in OA and offer practical suggestions to overcome these challenges.
The topics covered in this paper include subject selection, randomization, approaches to handling
missing data, subgroup analysis, sample size, and issues related to changing design mid-way through the
study. Special attention is given to standardizing the reporting of results and economic analyses.
Key ﬁndings include the importance of blinding and concealment, the distinction between superiority
and non-inferiority trials, the need to minimize missing data, and appropriate analysis and interpretation
of subgroup effects.
Investigators may use the ﬁndings and recommendations advanced in this paper to guide design and
conduct of randomized controlled trials of interventions for osteoarthritis.
© 2015 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
Researchers who design and conduct randomized controlled
trials to establish the efﬁcacy of treatments for OA should pay
special attention to several design features highlighted in this pa-
per: changes in trial design, blinding, deﬁning placebo, choice of
primary outcome and optimal time of outcome assessment, and
prevention of informative censoring. We provide recommenda-
tions to address these issues in the design and analytic stages
(Table I). We also highlight standardized reporting, economic
evaluation alongside clinical trials, and value of information anal-
ysis for prioritization of research.: E. Losina, Orthopedic and
Women's Hospital, 75 Francis
a), jonas.ranstam@gmail.com
ins), tjs@northwestern.edu
mposition of this work.
lf of Osteoarthritis Research SocietOsteoarthritis trials
Pharmacological treatment for OA consists both of symptom
modifying and structure modifying drugs. Non-pharmacologic
treatments generally focus on symptomatic relief and functional
restoration, but can also be evaluated for structural modiﬁcation,
using biochemical or imaging markers. For example, the IDEA trial
focused on efﬁcacy of weight management and exercise for pain
reduction, but also showed impact on inﬂammatory and MRI
biomarkers1.
For structure modifying interventions, clinical endpoints are
also important. For example, an endpoint of the structure modi-
fying intervention may be time to joint replacement. The bona ﬁde
clinical endpoint (e.g., reduction in joint space) may be substituted
by a biomarker if the treatment's effect on this biomarker correlates
with the treatment's effect on the bona ﬁde endpoint. This corre-
lation, the surrogacy value of the biomarker, must be shown before
the biomarker is used as a primary endpoint2.
Trials of symptom and structure modifying treatments typically
have a randomized, double blind, parallel group design. These trialsy International.
Table I
Recommendations to address methodologic challenges in osteoarthritis clinical trials
Domain Recommendation
Design Analysis
Selection of primary endpoint Clearly deﬁne primary outcome (endpoint), means of measuring, timing of
assessment. Ensure that selected outcome is acceptable by regulatory
organizations and scientiﬁc community. Do not select outcomes that did not
undergo a thorough evaluation regarding validity and reliability
Plan and execute primary analysis focused on selected a priori primary
outcome, which should be clearly and unambiguously deﬁned. Always
report results on primary outcome.
Choice of study design Decision between superiority and non-inferiority designs should be
governed by the novelty of treatment modality and choice of control group.
If the treatment modality under investigation is compared to placebo e
superiority design is the design of choice.
In situations where the treatment under investigation is compared to
another active treatment non-inferiority design are chosen if new treatment
is likely to have similar efﬁcacy but offers better tolerability and safety
proﬁle
Reporting should be consistent with chosen study design. The results of
superiority and, in particular, non-inferiority trials are best presented using
two-sided 95% conﬁdence intervals.
Blinding and Allocation Concealment When possible, both participants and the research team should be blinded
to treatment assignment. When this is not possible, those ascertaining the
outcome and analyzing the data should be blinded. Design features such as a
varying block randomization scheme and sequentially numbered, opaque,
sealed envelopes should be utilized to ensure allocation concealment.
Unblinding of data should not take place until the trial is terminated and
data are cleaned to an acceptable level of quality. If an interim analysis is
performed, this must be a completely conﬁdential process by independent
statisticians and conducted with blinded data.
Randomization Randomization should be performed using a computer random number
generator, incorporating strategies to ensure concealment (e.g., varying
random blocks, sequentially numbered, opaque sealed envelopes).
Primary analysis should use intention to treat principal, at least in
superiority trials. The ITT population plays a slightly different role in non-
inferiority trials. It is usually a good recommendation to present results for
both the ITT population and the per-protocol population.
Sample size Careful sample size calculations should be made before the start of the RCT,
and should take into account the hypothesized difference in primary
outcome between the treatment and control groups and the variability in
outcome. It is important that investigators consider an effect size that is
realistic, but also clinically important. Sample size calculations should also
take into account secondary outcomes and subgroup analyses.
In some cases analytic sample size calculations cannot be easily performed
because of methodological complexity. It may then be a good alternative to
use sample size simulation instead.
Missing data Strategies should be put in place at the design phase to minimize missing
data. These include limited burden of data collection on study participants,
incentives, and clear protocols for study staff to follow for contacting
participants. Detailed reason for dropout should be recorded, and
participants wishing to discontinue their assigned intervention should be
given the opportunity to continue study assessments.
Last observation carried forward and complete case analyses require strong
assumptions and should be avoided unless there is strong justiﬁcation.
Likelihood-based approaches such as mixed-effects models and multiple
imputation are valid approaches when the missing data is MAR. Sensitivity
analyses should be utilized to assess the robustness of the results to this
assumption.
When to consider design changes Design changes should be kept to a minimum and be pre-speciﬁed in the
study protocol. Such pre-speciﬁed design changes are usually initiated by
the results of an interim analysis, especially regarding the sample size and
termination of a trial.
Interim analyses may be logistically complicated as they usually require
independent statistical analysis. Avoid interim analyses, especially if they
are not pre-speciﬁed.
Reporting The study protocol can be published in a journal, and a short version of it
should be registered at a public trial registry accepted by the ICMJE and
WHO prior to the ﬁrst patient's randomization.
The statistical analysis and results reporting should comply with the
CONSORT statement's requirements and methodological recommendations
provided by regulatory authorities. When submitting a manuscript to a
scientiﬁc journal, include a copy of the study protocol and a completed
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treatments are also recommended to have an established active
comparator as a ‘usual care’ control3. Due to ethical considerations
the comparison with placebo in the presence of another active
treatment that has been shown to be more efﬁcacious than placebo
is not advisable. The goals of the equivalence or non-inferiority
trials are to show that the new treatment is no worse than
accepted active comparator, or, in the case where new treatment is
compared with placebo, that all treatment effect is just due to
placebo. The planning and conducting of such trials may include
discussions about interim analyses and design changes. To ensure
success of the trial, it is critical to deﬁne the key clinical hypothesis
of interest and design the trial to provide conclusive results
regarding this hypothesis.Allocation concealment and blinding
The purpose of concealed allocation is to avoid selection bias.
Investigators should provide sufﬁcient detail on how allocation
concealment was achieved so the reader can determine the likeli-
hood of success. The assessment of treatment concealment is
especially relevant in RCTs with subjective patient reported out-
comes. Allocation concealment means that the person imple-
menting randomization does not know or can't predict the next
treatment allocation. It reinforces the value of randomization in
reducing selection bias.
Blinding refers to the fact that the study participant does not
know what treatment he/she is getting. Double blinding means
that participants and investigators are unaware of treatment
assignment; this may be challenging to achieve in studies of
physical therapy, behavioral therapy, weight management, and
exercise. When it is hard to blind study participants or intervention
providers to the treatment assignments, several steps can be taken:
(1) those who ascertain outcomes should be blinded to treatment
arm allocation; (2) study participants should be advised not to
discuss treatment details with outcome assessors; (3) providers
delivering the intervention should not participate in outcome
assessment; and (4) in studies with active and control in-
terventions, both arms should be portrayed to participants as
‘active’ and intended to reduce symptoms or improve function.
We recommend that a plan for allocation concealment should
be an integral part of the manual of operating procedures (MOOP).
The minimum methodological standards of ensuring allocation
concealment include randomization schema using varying block
size implemented centrally; and, sequentially numbered, opaque,
sealed envelopes (SNOSE). Additional means of ensuring allocation
concealment include: protocols that clearly state that the informed
consent and baseline assessment are done prior to randomization,
inclusion of reports describing means of allocation concealment in
the manuscripts and report of baseline comparisons between arms
on the established prognostic factors.Randomization and stratiﬁcation
Another rationale for randomization is to avoid possible de-
pendencies between consecutive patients and obtain valid variance
estimates. Randomization prevents systematic imbalance of
measured and unmeasured baseline characteristics. To avoid
random imbalance in important prognostic factors, the randomi-
zation should be stratiﬁed on these factors. This design issue should
then also be taken into account in the statistical analysis. We
recommend, depending on sample size, to stratify the randomiza-
tion on a few known prognostic factors, taking into consideration
that stratiﬁcation without blocking is ineffective.Placebo effect vs trial effect
Often, individuals seek trial participation when their symptoms
ﬂare. Baseline ﬂare can affect interpretation of study results since
OA pain often is episodic. Building in an observation period of 1e2
weeks could help to distinguish the ‘trial’ effect from placebo or
attention control effect. During this initial observation period, all
participants could be exposed to attention control.
Regression to the mean occurs when the inclusion criteria are
broad and some participants have an extreme initial value of a
variable that is imperfectly correlated with subsequent measure-
ments due to measurement error or biological variation. If these
participants are measured again we may observe that the mean of
this “extreme” subgroup is closer to the mean of the original
sample. For example, a ﬁrst high blood pressure measurement on a
subject will tend to be closer to the average at the next measure-
ment of that subject. The same can occur with a serum biomarker.
The more the value deviates from the population mean and the
lower the correlation between the initial and subsequent mea-
surement, the larger the regression4. As a consequence, within-
group change could be exaggerated and difﬁcult to interpret. We
recommend that the evaluation of treatment effects should thus
not be based on within-group change but on between-group
comparisons. In addition, the pre-treatment observation period
can help distinguish true treatment effects from regression to the
mean.
It is imperative to distinguish achieving symptomatic relief vs
sustaining pain relief. The initial observation period is helpful to
reduce the impact of ﬂare on efﬁcacy in achieving relief. There is
presently no accepted standard for minimal duration of effect
required to establish sustainability; this issue is worthy of discus-
sion in the clinical trial community. We recommend that trial
planning activity should include careful collection of preliminary
data or secondary analysis of prior studies to establish a reliable
pattern of pain trajectories over time, in studies where pain is the
primary outcome.
Choice of outcomes
It is important to center the study on outcomes that are
meaningful to the patient and lead to appreciable improvements in
quality of life. One lively debate regarding the choice of primary
outcome centers on observed measures of functional performance
vs self-reported measures of pain, function, and other domains. We
summarize key elements of performance-based and self-report
outcomes to help guide such deliberations.
Performance-based or objective outcomes: These measures
involve an observer-based assessment of speciﬁc tasks such as
walking a set time or distance, arising from a chair, and the like. A
recent meta-analysis showed that several of these measures
including 40 m self-paced walking test and timed up and go tests
had the best psychometric properties among uni-dimensional
performance-based measures5.
Patient-oriented or subjective outcomes: More recently, greater
attention has been given to ascertainment of outcomes that are
meaningful and important to patients with OA. In contrast to
performance-based outcomes, the patient reported measures
assess patient perceptions of functional status, pain, and other
domains. Several established self report measures used frequently
in OA research include Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC) for lower extremity arthritis,
the Knee Injury and Osteoarthritis Score (KOOS) and Hip Injury
and Osteoarthritis Score (HOOS), and more recently the Patient
Reported Outcome Measurement Information System (PROMIS-
29) (and other aggregations of PROMIS measures)6e8. PROMIS-29
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OA is likely to affect, including functional limitations, pain inter-
ference and intensity, ability to fulﬁll desired social roles, anxiety
and depression, sleep disturbance and fatigue. It is noteworthy
that the PROMIS initiative also includes a suite of assessments
conducted using computer adaptive testing and invoking item
response theory. Each participant is given a limited number of
items, with the degree of difﬁculty of the item based upon re-
sponses to prior items. We recommend that the rationale for
primary endpoint be clearly delineated in study protocol alongside
with the validated means of measuring the primary endpoint.
Planning trials/sample size calculations
Sample size refers to the minimal number of participants
required to establish efﬁcacy with a speciﬁed level of conﬁdence
that the observed difference between intervention and control
cannot be ascribed to chance. Careful sample size considerations
require clear understanding of the magnitude of the effect that is
perceived as clinically important. This ensures that an unneces-
sarily large sample will not lead investigators to overstate the
importance of small effects that are unlikely to be clinically
meaningful, even with P-values below a critical threshold (e.g.,
0.05)9,10. Conversely, ensuring that the trial is appropriately pow-
eredwill allow investigators to distinguish between a negative trial,
meaning that the data did not suggest that the outcome differs
between the control and intervention arms, and an underpowered
trial, in which clinically meaningful differences were observed but
did not achieve statistical signiﬁcance. That is, “Absence of evidence
is not evidence of absence.” The adequacy of the sample size has of
course also important economical and ethical implications.
Technically, the assessment of sample size is usually based on a
two-sided hypothesis test of the primary endpoint (or on a two-
sided conﬁdence interval). If a one-sided test (or conﬁdence in-
terval) will be used in the analysis, the International Conference on
Harmonization of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH) recommendation is to use a
signiﬁcance level of half the one that would have been used for a
two-sided test (and equivalently for a one-sided conﬁdence inter-
val). The sample size is then calculated from the deﬁned Type I
error rate (false positive; usually 5%) and type 2 rate (false negative;
usually 10e20%), an estimate of the endpoint's variability, and the
smallest treatment effect to be detected in the trial.
As several different patient number scenarios are required to
evaluate the consequences of the uncertainty in the used estimates,
to achieve a robust study design, a computer program for sample
size calculation can be recommended for the calculation. Such
programs are included in most statistical software packages.
Feasibility assessment
Sample size estimation should be accompanied by parallel
assessment of study feasibility. The feasibility assessment should
take into consideration the number of eligible patients seen in a
particular clinic or other setting over the course of a speciﬁed unit
of time (e.g., week, month, year), the intensity of the study (time
commitment, intensity of the intervention), and the willingness of
eligible participants to take part in an RCT11,12. The feasibility
assessment offers critical insight into the anticipated duration of
enrollment and necessity to recruit additional centers.
Subgroup analysis and multiplicity issues
A subgroup analysis addresses the hypothesis that the efﬁcacy of
the regimen under study may be greater (or worse) in particularsubgroups. Such a hypothesis implies that treatment success is
greater in the presence of certain factors than in the absence of
those factors. Examples might include a speciﬁc trait such as severe
malalignment or obesity in persons with knee OA or number of
affected joints in persons with hand OA.
As recommended by the CONSORT guidelines (Consolidated
Standards of Reporting Trials checklist to improve the quality of
reporting of RCTs)16, only pre-planned subgroup analyses should be
undertaken. Multiple testing increases the chances of a false posi-
tive result (Type I error), but the Type I error rate can be controlled
by adjusting the statistical signiﬁcance level of each analysis ac-
cording to the number of tests conducted. It is necessary to have a
pre-speciﬁed description of conﬁrmatory analyses documented in
the study protocol or the statistical analysis plan (SAP). A simple
Bonferroni correction for multiple testing requires that the
threshold for signiﬁcance be divided by the number of tests. For
example, a study with ﬁve pre-planned subgroup analyses would
adjust the signiﬁcance threshold to 0.05/5 ¼ 0.01 for each analysis
in order to maintain an overall Type I error of 0.0517. The
Bonferroni-Holm procedure is a less conservative option for mul-
tiple testing adjustment18. All conﬁrmatory analyses should be
stated in the original registration of the RCT on ClinicalTrials.gov or
other trial registries.
Planning for subgroup analyses alongside an RCT often requires
a larger sample size. Studies powered to detect a main effect are
unlikely to have sufﬁcient sample size to detect interaction effects
or establish the presence of a prognostic factorwith sufﬁcient levels
of statistical certainty. Caution should be exercised in interpreting
and reporting the results of subgroup analyses when the study has
not been powered to detect an interaction effect. In these circum-
stances, lack of statistical signiﬁcance due to low statistical power
can be misinterpreted as evidence of the absence of the differential
efﬁcacy among subgroups19. Additional non-pre-speciﬁed sub-
group analyses can also be performed, but should be clearly re-
ported as exploratory.
We recommend that the decision to conduct a pre-speciﬁed
subgroup analysis in RCTs should be justiﬁed by prior data sug-
gesting that a potential prognostic factor either promotes or in-
hibits the hypothesized mechanism of effect of the intervention.
Conﬁrmation that a potential prognostic factor indeed is associated
with differential efﬁcacy should be supported by a formal statistical
test for interaction20.
Missing data prevention and handling
To minimize dropouts, investigators may discuss during the
design phase the minimum follow-up duration that would be
clinically meaningful without straining both study participants and
personnel. Ways tominimize study dropouts include offering study
participants the opportunity to complete visits in person or by
phone, accommodating participant schedules, offering reimburse-
ment for travel and/or parking, and modest incentive stipends for
participation. It is also important to establish protocols to ensure
that research staff exert the maximal effort permitted by the gov-
erning ethics body to obtain follow-up data from participants. Clear
protocols for research staff to follow in contacting study partici-
pants, such as the number of contact attempts, should be outlined
at the beginning of the study21.
Detailed reasons for dropout should be recorded if a participant
requests withdrawal. Reasons may include a participant's assess-
ment that he/she is too busy to continue participating, lack of ef-
ﬁcacy, side effects (e.g., injury sustained during exercise), etc. This
level of detail is especially important if reasons for dropout differ
between treatment arms. Collecting detailed reasons for dropout
will allow investigators to better understand the dropout
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outcome22. Participants wishing to discontinue their assigned
intervention should be offered the opportunity to continue study
assessments, facilitating intention-to-treat (ITT) inferences. ITT
implies that subjects are analyzed according to the arm random-
ized, irrespective of the actual treatment they received. The number
of participants dropping out and reasons for dropout should be
reported for each arm.
Missing data could lead to reduction of the sample size which in
turn may affect statistical power of the study. Further, missing
observations, if available, could have more extreme values that
would, in turn affect the estimation of the variability of the effect
and could artiﬁcially narrow the conﬁdence interval for the treat-
ment effect.
While last observation carried forward (LOCF) and complete
case (CC) analytic approaches are frequently used in the analysis of
RCTs, both require strong, and often unrealistic, assumptions about
the missing data mechanism. In particular, both methods require
that the missing data be missing completely at random (MCAR) e
that is, that the missing data are completely independent of
observed or unobserved measurements (dependent or indepen-
dent variables). This implies that study completers are a random
sample of the original study cohort. The less restrictive missing at
random (MAR) assumption is oftenmore reasonable. MAR assumes
that dropout may depend on observed outcomes or covariates, but
does not depend on unobserved data. For example, in a study of
physical function in patients with knee OA, older participants may
bemore likely tomiss follow-up visits. Older patientsmay also have
more functional limitations. Thus, simply examining observed
function could lead to a biased estimate e observed functionwould
be an overestimate of physical function in the cohort, since older
patients, with lower function, are more likely to be missing. How-
ever, if given a participant's age, missingness is independent of
function, the data are said to be missing at random. That is, the
missingness depends on observed data (age) but not the missing
data (function).
Under the MAR assumption, likelihood-based approaches such
as mixed-effects models will produce valid inferences. Multiple
imputation (MI) is another strategy that is valid under MAR. In this
case, a range of plausible values is imputed for the missing out-
comes using a prediction equation. This equation can incorporate
ancillary information about missing data, including observed out-
comes up until time of dropout, and reason for dropout. One of the
reasons MI is superior compared to simple imputation methods,
such as Last Observation Carried Forward, is that LOCF leads to
underestimated variance and inﬂated statistical signiﬁcance.
While there is no statistical test to verify the MAR assumption,
its appropriateness should be investigated by reviewing the
dropout reasons22. It is possible that data will be missing not at
random (MNAR), meaning that missingness is related to unob-
served outcomes. This is also termed informative censoring.
Sensitivity analyses should be utilized to assess the robustness of
the results to this assumption.
Since there is no simple statistical solution to handling data
missing not at random, we underscore the importance of mini-
mizing missing data at the design and implementation phases of
RCTs.
Interim analysis
Interim analyses may compromise the scientiﬁc value of an RCT
by inﬂating the Type I error rate. Also, conditioning the effect
estimation on interim observations may bias both the effect esti-
mate and its variance if the trial is terminated early. Interim ana-
lyses should therefore generally be avoided. If an interim analysis isplanned, it should be described in the study protocol and per-
formed in a way that protects the Type I error rate.
We recommend that the performance of the interim analysis
must be a conﬁdential process authorized and conducted by an
independent statistician and decision making committee, such as
Data Safety and Monitoring Board. It also means that multiplicity
adjustments are likely to be necessary.
Stopping a trial early for reasons of efﬁcacy or safety concerns
Interim analyses are used to interpret accumulating information
during a trial, often to investigate whether to terminate the trial at
an early stage. The analysis can reveal whether the treatments
already have convincingly established different e or similar e
treatment effects, or that they have too severe side effects.
The group sequential trial design allows repeated testing of
treatment effect, but trials designedwith an interim analysis as part
of a conventional design are often planned with only one interim
analysis. The decision to stop a trial early should focus both on the
primary endpoint as well as consistency among secondary end-
points and safety data.
Some participants may have incomplete follow up at the time of
the interim analysis and thus not be included in the interim anal-
ysis. When their follow up is completed, and they are included in a
new analysis, the outcome of the trial may differ. When an interim
analysis leads to early stopping, the ﬁnal results that include these
additional subjects are considered more important than the results
from the interim analysis, which excluded these subjects.
Futility stopping
An interim analysis may also include an evaluation of whether
or not the trial can achieve its objectives. If the interim results
indicate that the trial is unlikely to achieve statistical signiﬁcance,
stopping it can save important resources23. Such futility testing is
often performed on the primary or a suitable intermediate
endpoint and based on forecasting the outcome of a reference test
using conditional or predictive power. It is important to recognize
that Type I error usually is not protected if a trial is continued when
the interim analysis suggests stopping the trial for futility24.
Change in trial design
Changes that occur after the ﬁrst patient is randomized can
compromise the scientiﬁc integrity of a trial. In some cases, how-
ever, such changes can lead to better use of resources or shorter
study time. An adaptive trial is based on a study protocol that in-
cludes detailed description of one or more pre-planned interim
analyses and corresponding design modiﬁcations that can be made
with full control of the Type I error rate24. Adaptive trials can in-
crease the effectiveness and reduce the costs of new treatments,
but they have limitations2. When considering modifying an
ongoing trial the complete trial recommendations of the
ICH recommendations should be taken into account2.
Reassessing sample size
When an interim analysis neither shows superiority with regard
to efﬁcacy, nor suggests that a continuation of the trial would be
futile, a sample size reassessment may be useful. Sample size
calculation performed with an empirical based variance estimate is
likely to be more informative than one performed with a hypo-
thetical variance. However, a sample size reassessment that is
based on the result of an ongoing trial may inﬂate the Type I error
rate. Adjustment to account for the inﬂated Type I error will
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affect the Type I error rate should be used, such as one that does not
require unblinding of the data. Sample size re-estimation should be
done by a study statistician, with the rest of the investigative team
blinded.
Since unblinding trial data in an interim analysis has several
disadvantages, we recommend that it should be avoided when
reassessing sample size. Several methods exist, the simplest one
just ignoring treatment allocation and using a one-sample vari-
ance estimate25e27. This variance estimate may be biased when a
treatment effect exists, but a bias adjustment can be made with
the treatment effect assumed (under alternative hypothesis) in
the sample size calculation when calculating the type 2 error
rate27.Superiority and non-inferiority
Statistically nonsigniﬁcant outcomes in trials designed to show
that one treatment is superior to another are often wrongly inter-
preted as a proof of no difference between treatments. Equality of
treatment effects can never be proven with statistical methods.
Instead, equivalence and non-inferiority trials are designed to show
that two treatments are not “too different”, or that a new treatment
is not “unacceptably worse” than a standard one28. While the null
hypothesis in a superiority trial is that treatment effects are iden-
tical, the null hypothesis in an equivalence or non-inferiority trial is
deﬁned with reference to a speciﬁc difference in treatment effects,
the equivalence, or non-inferiority, margin. The thresholds for not
“too different” or not “unacceptably worse” are deﬁned using
clinical criteria. When the research team envisions that both su-
periority and non-inferiority approaches might be appropriate, the
trial should be powered as a non-inferiority trial, and the switching
from non-inferiority to superiority should be planned and
described in the protocol a priori. The superiority and non-
inferiority approaches also differ with regard to the role of the
study population. As the ITT population tends to be less conser-
vative than the per-protocol population in non-inferiority trials, the
latter is often chosen as the primary study population.
We recommend that if, after a successful interim analysis, a non-
inferiority trial is continued in order to show superiority, the ﬁnal
conclusion of the trial should be based on all collected data, even if
this result happens to be less supportive than the one from the
interim analysis.Changing primary endpoint
If important scientiﬁc knowledge has been gained after the
initiation of a trial, it may be appropriate to incorporate this
knowledge into the trial29. For example, consider a pharmaceutical
trial in OA patients inwhich the primary outcome is the change in a
serum biomarker associated with radiographic progression. If a
valid, and more responsive biomarker became available during the
course of the trial, it might be reasonable to consider adding this
new biomarker to the trial endpoints.
The main principle when considering changing the primary
endpoint is whether the change is independent of the data
collected in the trial. In some large trials with long duration, it may
be appropriate to change an endpoint even if the change depends
on data. The trial would then have to be divided into two stages, the
ﬁrst being hypothesis generating (endpoint identifying), the second
hypothesis testing (conﬁrmatory), and the outcome of the trial
relying entirely on the second stage. The design change, like other
major changes, should be documented in an amendment to the
study protocol.Other major design changes
Other changes, such as treatment duration, co-medications,
changes of inclusion or exclusion criteria, may be necessary in an
ongoing trial. In some cases, the changes affect the sample size. If
such changes are made, a formal protocol amendment should be
made, and the primary analysis should be stratiﬁed according to
whether the patients were randomized before or after the
change24. Homogeneity of the results should be carefully investi-
gated, but a combination of the results would still require careful
argumentation.
Analyzing and reporting RCT data
Analysis and reporting of results from a RCT should be con-
ducted according to the guidelines proposed by the CONSORT
group for pharmacologic studies and CLEAR NPT (CheckList to
Evaluate A Report of a NonPharmacological Trial) group for non-
pharmacologic studies using the ITT analysis as the primary ana-
lysis12,16,30e38. In the intention-to- treat analysis, all study partici-
pants are analyzed according to treatment arm to which they were
randomized, taking advantage of the balance in measured and
unmeasured factors.
Study teams have an ethical obligation to report the results of
their research activities39. The manner in which study data are
reported has evolved signiﬁcantly over the past 20 years, and there
is general consensus today of the basic requirements. All studies
should be prospectively entered into an appropriate clinical trials
registry. There are numerous country and region-speciﬁc registries,
and the world health organization (WHO) maintains the Interna-
tional Clinical Trials Registry Platform (ICTRP), whose main aim is
“to facilitate the prospective registration of the WHO Trial Regis-
tration Data Set on all clinical trials, and the public accessibility of
that information (http://www.who.int/ictrp/en/ Accessed on
04Jun2014).” In the United States, registration is required for trials
that meet the Food and Drug Administration Amendments Act
(FDAAA) deﬁnition of an “applicable clinical trial”40. “Applicable
Clinical Trials” include trials of drugs, biologics and devices, other
than phase 1 studies, of agents that are subject to FDA regulation
and that have one or more sites in the United States, are conducted
under an FDA Investigational New Drug (IND) or Investigational
Device Exemption (IDE) or involves a drug, biologic or device
manufactured in the United States and exported for research. Trials
must be registered within 21 days of the ﬁrst participant being
enrolled. Clinicaltrials.gov is a web-based registry resource (“Fact
sheet, ClinicalTrials.gov”. U.S. National Library of Medicine. May 3,
2011. Last accessed 04Jun2014) developed as a consequence of the
Food and Drug Administration Modernization Act of 1997
(FDAMA)41 and maintained by the National Library of Medicine, a
part of the National Institutes of Health. The data entered are
publicly available. The scope of clinical trials that must be regis-
tered and the information provided, including study results, has
been signiﬁcantly expanded since its initiation. Timely registration
of clinical trials has become a requirement from the majority of
scientiﬁc journals for acceptance of manuscripts reporting study
results and is a long-standing recommendation of the International
Committee of Medical Journal Editors (ICMJE)42.
Less consensus exists at this time regarding what speciﬁc clin-
ical trials information should be made publicly available. Interna-
tionally, the WHO Registry Platform Working Group on the
Reporting of Findings of Clinical Trials supports that “the ﬁndings of
all clinical trials must be made publicly available” but has provided
no speciﬁc template or recommendations43. In the United States,
Section 801 of the FDAAA requires the submission of “basic results”
for certain clinical trials, generally not later than 1 year after study
E. Losina et al. / Osteoarthritis and Cartilage 23 (2015) 677e685 683completion44. As a consequence, the clinicaltrials.gov results
database was implemented and allows the submission of data in a
standard, tabular format consisting of sections dealing with
participant ﬂow, baseline characteristics, outcome measures and
statistical analyses and adverse events. The sponsor or principal
investigator is responsible for submitting these data. Details are
provided at http://prsinfo.clinicaltrials.gov/and the article by Tse
et al.44.
The information content to be reported in publications con-
tinues to elicit discussion, with the CONSORT statement45 currently
serving as a widely accepted standard for the reporting of clinical
trials. The statement includes an evidence-based set of recom-
mendations, presented as a 25-item checklist and ﬂow diagram. An
accompanying “explanation and elaboration document”46 provides
the principles upon which the recommendations were generated
and offers valuable information to assist in ensuring the quality of
reporting of clinical trials in the literature. Extensions of the CON-
SORT statement to randomized controlled trials that differ from the
standard parallel-group design have recently been published
(http://www.consort-statement.org/extensions Accessed on
04Jun2104). Many scientiﬁc journals now strongly suggest or
require that submitted manuscripts adhere to the CONSORT prin-
ciples, checklist and ﬂow diagram. Details regarding the CONSORT
group and its activities are available from its website47. Guidelines
for data content and the structure of reports required for ﬁlings to
regulatory authorities are beyond the scope of this update but can
be accessed by those interested (guideline document of ICH48 and
guidance document of FDA (U.S. Food and Drug Administration.
Clinical Trials Guidance Documents. Available from: http://www.
fda.gov/RegulatoryInformation/Guidances/ucm122046.htm)).
Economic evaluations alongside RCTs in osteoarthritis
When trial results indicate that an intervention is efﬁcacious,
policy makers must decide whether the treatment offers good
value for the additional resources spent49e53. To address this
question, investigators may consider a formal cost-effectiveness or
cost-utility analysis alongside clinical trials or beyond the time-
frame of the trial54,55.
OA treatments generally affect quality of life, not longevity.
Therefore, investigators considering economic evaluation alongside
an RCT should include appropriate measures of quality of life in the
data collection instruments. In economic evaluations, quality of life
is quantiﬁed by utilities ranging from 0 to 1, with 1 corresponding
to perfect health and 0 to death56,57. Investigators should decide
whether assessment of utilities will be done directly, using the
Standard Gamble or Time-Trade-Off methods58, or derived indi-
rectly using instruments such as EuroQol or short form health
surveys (SF36 or SF12), WOMAC, with cross-mapping of health
states assessed with these measures to population-based re-
positories of preference-based utilities59e63.
Investigators should collect data related to subjects' health care
utilization and select a time frame over which patients can reliably
recall their utilization of health care. It is of paramount importance
to decide on the perspective (societal, government, payer, provider)
that informs the collection of the cost data. Questions related to
health care utilization should encompass visits to primary doctors
and specialists, medication use, hospitalizations, and emergency
department visits. It is important to account for direct medical and
indirect costs. Direct medical costs include pharmacological and
non-pharmacological regimens, ambulatory and emergency
department visits and inpatient stays. Indirect costs capture pro-
ductivity losses due to a medical condition.
The Panel on Cost-Effectiveness in Health and Medicine, rec-
ommends that cost-effectiveness analyses (CEA) be done over thelong term, potentially the lifetime, to capture long-term conse-
quences of treatment strategies. For example in the case of OA, a
key economic and quality of life outcome is total knee replace-
ment. Often, to conduct a CEA over a long time duration, data
from an RCT need to be augmented by data from other sources.
Decision analysis modeling should be employed in addition to
commonly used statistical methods to conduct a CEA over the
lifetime horizon.
Careful attention should be given to the investigation of un-
certainty in parameter estimates. Depending on the type of eco-
nomic evaluation (stochastic evaluation alongside of RCT or model-
based evaluation, beyond the time frame of the RCT) different types
of uncertainty should be considered. For the evaluation alongside of
the RCT, there are four main types of uncertainty: methodological,
sampling variation, extrapolation, and generalizability/trans-
ferability. The main methods to handle methodological and
generalizability/transferability concerns include the one- and
multi-way sensitivity analyses. Parameter uncertainty is more
relevant to model-based evaluations. The reduction of uncertainty
through additional research may improve decisions but comes at a
cost. Probabilistic sensitivity analyses followed by formal value of
information (VOI) analyses, a formal methodology that is designed
to facilitate establishing research priorities, evaluate the impact of
uncertainty, and the value of future research to reduce
uncertainty64.
The traditional cost-effectiveness analysis is designed to address
whether a treatment offers good value but does not provide insight
into affordability. This issue can be addressed with budget impact
analysis (BIA). The goal of BIA is to quantify the ﬁnancial conse-
quences of adopting the speciﬁc treatment strategy (such as a
weight loss program) by various payers, including insurance or-
ganizations, health care systems, and government, given real life
resource constraints. The BIA permits projection of howadoption of
the treatment could impact spending for speciﬁc payers. The results
of BIA are often used for budget planning and changes in health
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